PubMed (GeneRIF) for id: 54910

Year	Number of Results
2010	1
2011	1
2012	1
2013	1
2015	2
2016	2
2017	2
2018	1
2019	3
2020	4
2021	2
2024	0

1

Effect of microrna-138 on epithelial-Mesenchymal transition and invasion of breast cancer cells by targeting semaphorin 4C.

Liu H, Ye H, Li X. Liu H, et al. Bioengineered. 2021 Dec;12(2):10117-10125. doi: 10.1080/21655979.2021.2000733. Bioengineered. 2021. PMID: 34747314 Free PMC article.

2

Serum semaphorin4C as an auxiliary diagnostic biomarker for breast cancer.

Wang Y, Liu J, Li J, Li H, Li X, Qiao L, Yang J, Fang T, Chen S, Ma J, Wan J, Li X, Zhang L, Xia Y, Wu Y, Xu T, Shao J, Feng Y, Kamel IR, Yang Q, Li Z, Gao Q. Wang Y, et al. Clin Transl Med. 2021 Aug;11(8):e480. doi: 10.1002/ctm2.480. Clin Transl Med. 2021. PMID: 34459126 Free PMC article. No abstract available.

3

High SEMA4C expression promotes the epithelial-mesenchymal transition and predicts poor prognosis in colorectal carcinoma.

Hou Y, Wang W, Zeng Z, Gan W, Lv S, Li T, Yan Z, Zhang R, Yang M. Hou Y, et al. Aging (Albany NY). 2020 Nov 7;12(21):21992-22018. doi: 10.18632/aging.104038. Epub 2020 Nov 7. Aging (Albany NY). 2020. PMID: 33177246 Free PMC article.

4

Semaphorin 4A, 4C, and 4D: Function comparison in the autoimmunity, allergy, and cancer.

Rajabinejad M, Asadi G, Ranjbar S, Afshar Hezarkhani L, Salari F, Gorgin Karaji A, Rezaiemanesh A. Rajabinejad M, et al. Gene. 2020 Jul 1;746:144637. doi: 10.1016/j.gene.2020.144637. Epub 2020 Mar 31. Gene. 2020. PMID: 32244055 Review.

5

Downregulation of SEMA4C Inhibit Epithelial-Mesenchymal Transition (EMT) and the Invasion and Metastasis of Cervical Cancer Cells via Inhibiting Transforming Growth Factor-beta 1 (TGF-β1)-Induced Hela cells p38 Mitogen-Activated Protein Kinase (MAPK) Activation.

Yang L, Yu Y, Xiong Z, Chen H, Tan B, Hu H. Yang L, et al. Med Sci Monit. 2020 Jan 17;26:e918123. doi: 10.12659/MSM.918123. Med Sci Monit. 2020. PMID: 31951596 Free PMC article.

6

Sema4C mediates EMT inducing chemotherapeutic resistance of miR-31-3p in cervical cancer cells.

Jing L, Bo W, Yourong F, Tian W, Shixuan W, Mingfu W. Jing L, et al. Sci Rep. 2019 Nov 27;9(1):17727. doi: 10.1038/s41598-019-54177-z. Sci Rep. 2019. PMID: 31776419 Free PMC article.

7

SEMA4C is a novel target to limit osteosarcoma growth, progression, and metastasis.

Smeester BA, Slipek NJ, Pomeroy EJ, Bomberger HE, Shamsan GA, Peterson JJ, Crosby MR, Draper GM, Becklin KL, Rahrmann EP, McCarthy JB, Odde DJ, Wood DK, Largaespada DA, Moriarity BS. Smeester BA, et al. Oncogene. 2020 Jan;39(5):1049-1062. doi: 10.1038/s41388-019-1041-x. Epub 2019 Oct 3. Oncogene. 2020. PMID: 31582836

8

Semaphorin 4C Promotes Macrophage Recruitment and Angiogenesis in Breast Cancer.

Yang J, Zeng Z, Qiao L, Jiang X, Ma J, Wang J, Ye S, Ma Q, Wei J, Wu M, Huang X, Ma D, Gao Q. Yang J, et al. Mol Cancer Res. 2019 Oct;17(10):2015-2028. doi: 10.1158/1541-7786.MCR-18-0933. Epub 2019 Jul 15. Mol Cancer Res. 2019. PMID: 31308149

9

Sema4C/PlexinB2 signaling controls breast cancer cell growth, hormonal dependence and tumorigenic potential.

Gurrapu S, Pupo E, Franzolin G, Lanzetti L, Tamagnone L. Gurrapu S, et al. Cell Death Differ. 2018 Jul;25(7):1259-1275. doi: 10.1038/s41418-018-0097-4. Epub 2018 Mar 19. Cell Death Differ. 2018. PMID: 29555978 Free PMC article.

10

miR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cells.

Song J, Li Y. Song J, et al. Cancer Sci. 2017 Jan;108(1):23-31. doi: 10.1111/cas.13104. Epub 2016 Dec 1. Cancer Sci. 2017. PMID: 27743413 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

16 results

Results by year